

WEST Search History

DATE: Friday, September 05, 2003

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L7	L6 and (quartnerary ammoni?)	11
<input type="checkbox"/>	L6	L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?))	34
<input type="checkbox"/>	L5	L3 and (deionized water)	34
<input type="checkbox"/>	L4	L3 and (nipagin or nipasol)	1
<input type="checkbox"/>	L3	L2 and ((propylene glycol) or glerol or glycol\$)	35
<input type="checkbox"/>	L2	L1 and (acetate? or citrate? or ascorbate? or phosphate?)	36
<input type="checkbox"/>	L1	ibandron\$ and (osteogen\$ or bone or osseous or skeletal\$)	253

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	AUG 22	Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL

NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:38:41 ON 05 SEP 2003

=> file caplus uspatful japio europatful medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:39:10 ON 05 SEP 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:39:10 ON 05 SEP 2003
 COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
 COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 15:39:10 ON 05 SEP 2003

FILE 'BIOSIS' ENTERED AT 15:39:10 ON 05 SEP 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 15:39:10 ON 05 SEP 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s ibandron? and (osteogen? or bone or osseous or skeletal)
 L1 1101 IBANDRON? AND (OSTEOGEN? OR BONE OR OSSEOUS OR SKELETAL)

=> s l1 and (acetate# or citr? or ascorbate# or phosphate#)
 L2 295 L1 AND (ACETATE# OR CITR? OR ASCORBATE# OR PHOSPHATE#)

=> s l2 and ((polyethylene glycol) or (propylene glycol) or (acid glyceride#))
 UNMATCHED LEFT PARENTHESIS 'AND ((POLYETHYLE'
 COMMAND STACK INTERRUPTED. ENTER "DISPLAY HISTORY"
 TO SEE WHICH COMMANDS WERE EXECUTED.

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s 12 and ((polyethylene glycol) or (propylene glycol) or (acid glyceride#))
L3 199 L2 AND ((POLYETHYLENE GLYCOL) OR (PROPYLENE GLYCOL) OR (ACID GLYCERIDE#))

=> s 13 and (nipagin or nipasol or borate? or boric?)
L4 47 L3 AND (NIPAGIN OR NIPASOL OR BORATE? OR BORIC?)

=> s 14 and (deionized water)
L5 20 L4 AND (DEIONIZED WATER)

=> s 15 and (sorbitol or sweetener# or adjvant# or excipient#)
L6 20 L5 AND (SORBITOL OR SWEETENER# OR ADJVANT# OR EXCIPIENT#)

=> d 16 1-20 ibib abs

L6 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:591663 CAPLUS
DOCUMENT NUMBER: 137:129921
TITLE: Liquid pharmaceutical composition containing
ibandronate for treating **bone**
diseases
INVENTOR(S): Uria, Guadalupe Martinez
PATENT ASSIGNEE(S): Riderway Corporation, Panama
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1228761	A2	20020807	EP 2002-1959	20020201
EP 1228761	A3	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002142997	A1	20021003	US 2002-66008	20020201
JP 2002332235	A2	20021122	JP 2002-25725	20020201
BR 2002000291	A	20030701	BR 2002-291	20020201
PRIORITY APPLN. INFO.:			US 2001-265827P	P 20010201
			AR 2001-106109	A 20011228

AB A liq. pharmaceutical compn. and methods for use in the treating of **bone** diseases, comprise an aq. soln. contg. 0.05-35% by wt. of **ibandronic** acid or its salts, 0.1-5% by wt. of a pH regulating agent, 1-15% by wt. of a co-solvent, 0.005%-0.5% by wt. of a conserving agent, 1-90% by wt. of a **deionized water**, and **excipients** and pharmaceutically acceptable stabilizers, wherein the compn. has a pH of about 2-7. The compn. is formulated for sublingual administration and enteric administration. For example, a compn. for sublingual administration was prepd. by dissolving 1200 mg of monohydrate **citric acid** in **deionized water** to obtain equiv. to 22%, adding 2810 mg of aq. sodium **ibandronate** followed by 20 mg of **propylene glycol** with agitation, adjusting the pH to 2.4, and adding **deionized water** to bring the formulation to 100 g followed by filtering.

L6 ANSWER 2 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:259424 USPATFULL
TITLE: Liquid pharmaceutical composition for treating
bone diseases
INVENTOR(S): Uria, Guadalupe Martinez, Buenos Aires, ARGENTINA

PATENT ASSIGNEE(S): RIDERWAY CORPORATION (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142997	A1	20021003
APPLICATION INFO.:	US 2002-66008	A1	20020201 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265827P	20010201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., 805 Third Avenue, New York, NY, 10022	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	620	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a liquid pharmaceutical composition and methods for use in the treating of **bone** diseases, the composition being an aqueous solution comprising 0.05% to 35% by weight of **ibandrona**ic acid or salts thereof; 0.1% to 5% by weight of a pH regulating agent; 1% to 15% by weight of a co-solvent; 0.005% to 0.5% by weight of a conserving agent; 1% to 90% by weight of a **deionized water**; and **excipients** and pharmaceutically acceptable stabilizers, wherein the composition has a pH of about 2 to 7. The composition is formulated for sublingual administration and enteric administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:160717 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Newbury Park, CA, United States
Smith, Garry R., Limerick, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413955	B1	20020702
APPLICATION INFO.:	US 2000-677677		20001002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157490P	19991004 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3955	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory

arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:152632 USPATFULL

TITLE: .alpha.v integrin receptor antagonists

INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410526	B1	20020625
APPLICATION INFO.:	US 2000-583522		20000531 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137101P	19990602 (60)
	US 2000-179216P	20000131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3656	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:92700 USPATFULL

TITLE: Alpha v integrin receptor antagonists

INVENTOR(S): Arison, Byron H., Watchung, NJ, UNITED STATES
Cui, Donghui, Newton, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Subramanian, Raju, Perkasio, PA, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049224	A1	20020425
	US 6426353	B2	20020730
APPLICATION INFO.:	US 2001-952084	A1	20010914 (9)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2000-232344P 20000914 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1088

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting **bone** resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting **bone** resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:72890 USPATFULL
TITLE: Alpha V integrin receptor antagonists
INVENTOR(S): Coleman, Paul J., Wallingford, PA, UNITED STATES
Cui, Donghui, Newtown, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Landsdale, PA, UNITED STATES
Silva Elipe, Maria Victoria, Mountainside, NJ, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040030	A1	20020404
APPLICATION INFO.:	US 2001-953606	A1	20010914 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232262P	20000914 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1296	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R.dbd.H or Me), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting **bone** resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting **bone** resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:67236 USPATFULL
TITLE: Alpha V integrin receptor antagonists

INVENTOR(S): Duggan, Mark E., Schwenksville, PA, UNITED STATES
 Halczenko, Wasyl, Lansdale, PA, UNITED STATES
 Hutchinson, John H., Philadelphia, PA, UNITED STATES
 Li, Aiwen, Audubon, PA, UNITED STATES
 Meissner, Robert S., Schwenksville, PA, UNITED STATES
 Perkins, James J., Churchville, PA, UNITED STATES
 Steele, Thomas G., Schwenksville, PA, UNITED STATES
 Wang, Jiabing, Chalfont, PA, UNITED STATES
 Patane, Michael A., Billerica, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037889	A1	20020328
	US 6472403	B2	20021029
APPLICATION INFO.:	US 2001-766148	A1	20010119 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177168P	20000120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2835	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2002:57802 USPATFULL
 TITLE: Integrin receptor antagonists
 INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
 Hartman, George D., Lansdale, PA, United States
 Perkins, James J., Churchville, PA, United States
 Ihle, Nathan, Mercer Island, WA, United States
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358970	B1	20020319
APPLICATION INFO.:	US 2000-599088		20000621 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-140535P	19990623 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dentz, Bernard	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2558	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:17296 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010176	A1	20020124
APPLICATION INFO.:	US 2001-916977	A1	20010728 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69899P	19971217 (60)
	US 1998-83209P	19980427 (60)
	US 1998-92622P	19980713 (60)
	US 1998-108063P	19981112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5336	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2001:233621 USPATFULL
TITLE: Alpha V integrin receptor antagonists

INVENTOR(S): Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001053853	A1	20011220
APPLICATION INFO.:	US 2001-767471	A1	20010123 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177792P	20000124 (60)
	US 2000-230469P	20000906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4132	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel alkanolic acid derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:168133 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297249	B1	20011002
APPLICATION INFO.:	US 1999-453847		19991202 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-212082, filed on 15 Dec 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69899P	19971217 (60)
	US 1998-83209P	19980427 (60)
	US 1998-92622P	19980713 (60)
	US 1998-108063P	19981112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Rao, Deepak R.	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	

NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 4784

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2001:121485 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268378	B1	20010731
APPLICATION INFO.:	US 2000-498895		20000207 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69910P	19971217 (60)
	US 1998-83251P	19980427 (60)
	US 1998-92588P	19980713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Solola, Taofiq A.	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4460	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2001:71543 USPATFULL
TITLE: Bezazepine derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232308	B1	20010515
APPLICATION INFO.:	US 2000-496525		20000202 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-118428P	19990203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1967	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to benzazepine derivatives and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:48064 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211191	B1	20010403
APPLICATION INFO.:	US 1998-212510		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69909P	19971217 (60)
	US 1998-83250P	19980427 (60)
	US 1998-92630P	19980713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Jayaram, Beby	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3544	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting

vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:92099 USPATFULL
TITLE: Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Hutchinson, John H., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6090944		20000718
APPLICATION INFO.:	US 1999-371444		19990810 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96378P	19980813 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Higel, Floyd D.	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1,24	
LINE COUNT:	3589	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:64874 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066648		20000523
APPLICATION INFO.:	US 1998-212123		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69910P	19971217 (60)
	US 1998-83251P	19980427 (60)
	US 1998-92588P	19980713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	

ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli,
Anthony D.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:44101 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6048861		20000411
APPLICATION INFO.:	US 1998-212082		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69899P	19971217 (60)
	US 1998-83209P	19980427 (60)
	US 1998-92622P	19980713 (60)
	US 1998-108063P	19981112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli,
Anthony

NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 5443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor

growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:34557 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040311		20000321
APPLICATION INFO.:	US 1999-362528		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94478P	19980729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dentz, Bernard	
LEGAL REPRESENTATIVE:	Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2801	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting **bone** resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2000:9915 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017926		20000125
APPLICATION INFO.:	US 1998-212079		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69910P	19971217 (60)
	US 1998-83251P	19980427 (60)

US 1998-92588P 19980713 (60)
 US 1998-79197P 19980324 (60)
 US 1998-79944P 19980330 (60)
 US 1998-80397P 19980402 (60)
 US 1998-92624P 19980713 (60)
 US 1998-99948P 19980911 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Dentz, Bernard
 LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
 NUMBER OF CLAIMS: 48
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5668

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 20 EUROPATFULL COPYRIGHT 2003 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1228761 EUROPATFULL EW 200232 FS OS
 TITLE: Liquid pharmaceutical composition for treating bone diseases.
 Fluessige pharmazeutische Zusammensetzung zur Behandlung von Knochenerkrankungen.
 Composition pharmaceutique liquide pour le traitement de maladies osseuses.
 INVENTOR(S): Uria, Guadalupe Martinez, Avenida Juan B. Justo 4840 (1416), Capital Federal, AR
 PATENT ASSIGNEE(S): Riderway Corporation, Elvira Mendez, Edificio Villarino, Piso 6, Panama, PA
 PATENT ASSIGNEE NO: 4010580
 AGENT: Frohwitter, Bernhard, Dipl.-Ing., Patent- und Rechtsanwaelte, Postfach 86 03 68, 81630 Muenchen, DE
 AGENT NUMBER: 150675
 OTHER SOURCE: BEPA2002066 EP 1228761 A2 0011
 SOURCE: Wila-EPZ-2002-H32-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1228761	A2	20020807
		20020807
EP 2002-1959		20020201
US 2001-265827		20010201
AR 2001-106109		20011228

'OFFENLEGUNGS' DATE:

APPLICATION INFO.:

PRIORITY APPLN. INFO.:

East

	Inventor	S	C	P	2	3	4	5	Image Doc. Displayed	PT
1	Uria, Guadalupe Martinez	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	US 20020142997	<input type="checkbox"/>

Freeform Search

Database:
 US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term: L6 and (quartnerary ammoni?)

Display: 10 Documents in **Display Format:** - Starting with Number 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Interrupt

Search History

DATE: Friday, September 05, 2003 [Printable Copy](#) [Create Case](#)

Set Name <small>side by side</small>	Query	Hit Count	Set Name <small>result set</small>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L7</u>	L6 and (quartnerary ammoni?)	11	<u>L7</u>
<u>L6</u>	L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?))	34	<u>L6</u>
<u>L5</u>	L3 and (deionized water)	34	<u>L5</u>
<u>L4</u>	L3 and (nipagin or nipasol)	1	<u>L4</u>
<u>L3</u>	L2 and ((propylene glycol) or glerol or glycol\$)	35	<u>L3</u>
<u>L2</u>	L1 and (acetate? or citrate? or ascorbate? or phosphate?)	36	<u>L2</u>
<u>L1</u>	ibandron\$ and (osteogen\$ or bone or osseous or skeletal\$)	253	<u>L1</u>

END OF SEARCH HISTORY

	Type	L #	Hits	Search Text	DBs	Time Stamp
1	BRS	L1	253	ibandron\$ and (osdtegen\$ or bone or osseous or skeletal\$)	USPAT; US-PGP UB; EPO; JPO; DERWEN T; IBM_TD B	2003/09/05 19:38
2	BRS	L2	253	ibandron\$ and (osteogen\$ or bone or osseous or skeletal\$)	USPAT; US-PGP UB; EPO; JPO; DERWEN T; IBM_TD B	2003/09/05 19:39
3	BRS	L3	148	12 and (acetate? or citrate or ascorbate? or phosphate?)	USPAT; US-PGP UB; EPO; JPO; DERWEN T; IBM_TD B	2003/09/05 19:39
4	BRS	L4	148	13 and ((propylene glycol) or glycerol or glycol\$ or (polyethylene glycol) or (acid glyceride?))	USPAT; US-PGP UB; EPO; JPO; DERWEN T; IBM_TD B	2003/09/05 19:41
5	BRS	L5	1	14 and (nipagin or nipasol or borate? or boric?)	USPAT; US-PGP UB; EPO; JPO; DERWEN T; IBM_TD B	2003/09/05 19:42

	Comments	Error Definition	Errors
1			0
2			0
3			0
4			0
5			0

	Title	Current OR	Current XRef	Retrieval Classif
1	Liquid pharmaceutical composition for treating bone diseases	514/102		

	U	1	Document ID	Issue Date	Pages
1	<input type="checkbox"/>	<input type="checkbox"/>	US 20020142997 A1	20021003	7